Drugs / aluminium hydroxide
aluminium hydroxide
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02797236 | Sep 2016 → Jun 2017 | shigellosis | Institut Pasteur | Completed | No outcome recorded |
| Phase 1 | NCT02787109 | Jul 2016 → Jul 2017 | chlamydia trachomatis infectious disease | Statens Serum Institut | Completed | No outcome recorded |
| Phase 1 | NCT00562237 | Jul → Nov 2007 | — | Solvay Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00509158 | Oct 2007 → Oct 2008 | — | Radboud University Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03998592 Background | May 2021 → Mar 2022 | rheumatic fever | Butantan Institute | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01336530 Comparator | Apr 2011 → Jan 2017 | radiation-induced disorder | MEDA Pharma GmbH & Co. KG | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aluminium-hydroxide | “582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.” NCT01336530 ↗5“CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration” NCT02787109 ↗ “aluminium-hydroxide adjuvant concentrations” NCT00562237 ↗ “adjuvanted with aluminium hydroxide (alum)” PMID 33186516 ↗ Nov 2020 “Aluminium Hydroxide as adjuvant” NCT03998592 ↗ |
| Known as | Al(OH)3 | “CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration” NCT02787109 ↗ |
| Known as | alum | “adjuvanted with aluminium hydroxide (alum)” PMID 33186516 ↗ Nov 2020 |
| Modality | Other / unclassified | “aluminium-hydroxide adjuvant concentrations” NCT00562237 ↗ |
| Route | Oral | “Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.” NCT01336530 ↗ |